Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

•Patients achieve high SVR12 rates with sofosbuvir/velpatasvir/voxilaprevir after prior DAA failures. •Sofosbuvir/velpatasvir/voxilaprevir is a very safe and well tolerated combination. •GT3 cirrhotic patients with previous treatment with NS5A-inhibitors are poor responders. •GT3 is the only factor that impacts SVR12 rates in retreatment with sofosbuvir/velpatasvir/voxilaprevir. Background & Aims Around 5% of patients with chronic hepatitis C...